Action Tremor

Deep Brain Stimulation

Annual eReport to the South-Eastern Norway Health Authority

Oslo University Hospital

A Controlled Comparison of Two DBS Targets for Upper Extremity Action Tremor

Deep Brain Stimulation in Disabling Action Tremor: A Randomized, Double-blind Study Comparing the Ventral Intermediate Nucleus (VIM) of the Thalamus and the Posterior Subthalamic Area (PSA) / Zona Incerta (The TREMORSTIM Study)

The difference in the change from baseline to the end of each of the two 3-month randomized cross-over periods, in tremor of the contralateral upper limb(s), as evaluated by items 5,6,10-14 and 16-21 in the Fahn-Tolosa-Marin (FTM)-score with VIM- versus PSA-stimulation.

2) The difference in the change from baseline to the end of each of the two 3-month cross-over periods in the items scoring tremor of face/tongue/voice/trunk/lower limb(s), with VIM- versus PSA-stimulation.

Change from baseline to 1-yr with stimulation at the most optimal of 4 electrode contacts of each patient (selected after the second randomization period) of the total FTM-score, tremor of the upper limb(s) (same items as above) and of the items scoring tremor in the face, tongue, voice, trunk, lower limb(s).

Change from baseline to 1-yr of Quality of Life in Essential Tremor (QUEST) scale, and Visual Analogue Scale of Global Disease Burden as assessed by the patient.

Frequency of serious adverse events (surgical complications and stimulation related side-effects), including eventual deterioration on neuropsychological testing , registered during the first year of stimulation.

Inger Marie Skogseid

Consultant, MDPhD

South-Eastern Norway Regional Health Authority

Randomized allocation of half the patients to be stimulated the first 3 months in the VIM-nucleus of the thalamus (VIM) and then 3 months in the posterior subthalamic area (PSA), and for the other half the first 3 months in the PSA and the next 3 months in the VIM

The doctor who assesses the primary outcome measures at 3 and 6 months and the participant are both unaware of which of the two targets is stimulated in the two randomization periods.

Essential Tremor and Parkinson's Disease patients with Tremor refractory to pharmacological therapy who underwent Magnetic Resonance guided Focused Ultrasound Surgery (MRgFUS)

Tremor

The Effect of Lesion Characteristics in MRgFUS on Tremor in Essential Tremor and Parkinson's Disease

The Effect of Lesion Characteristics in Magnetic Resonance Guided Focused Ultrasound Surgery (MRgFUS) on Tremor in Essential Tremor and Parkinson's Disease

Tremor score: In ET patients - Clinical Rating Scale for Tremor (CRST)

In PD patients - Motor part of Unified PD Rating Scale (UPDRS)

Quality of life: Quality of Life Essential Tremor Questionnaire (QUEST)

Parkinson's Disease Questionnaire (PDQ39)

For all patients: iSeismometer application for mobile phone for Assessment of tremor amplitude and frequency before and after the procedure.

essential tremor/ödəm

A Controlled Comparison of Two DBS Targets for Upper Extremity Action Tremor

The Effect of Lesion Characteristics in MRgFUS on Tremor in Essential Tremor and Parkinson's Disease

Elm tərəfindən dəstəklənən ən tam dərman bitkiləri bazası